These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 7873456)

  • 61. The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients.
    Jones AL; MacNeill F; Jacobs S; Lonning PE; Dowsett M; Powles TJ
    Eur J Cancer; 1992; 28A(10):1712-6. PubMed ID: 1389491
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Endocrine therapy for advanced breast cancer: a review.
    Muss HB
    Breast Cancer Res Treat; 1992; 21(1):15-26. PubMed ID: 1382723
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Aromatase inhibitors in the treatment of advanced breast cancer.
    Miller WR
    Cancer Treat Rev; 1989 Jun; 16(2):83-93. PubMed ID: 2527597
    [No Abstract]   [Full Text] [Related]  

  • 64. Oral 4-hydroxyandrostenedione, a new endocrine treatment for disseminated breast cancer.
    Cunningham D; Powles TJ; Dowsett M; Hutchison G; Brodie AM; Ford HT; Gazet JC; Coombes RC
    Cancer Chemother Pharmacol; 1987; 20(3):253-5. PubMed ID: 3677299
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: formestane versus megestrol acetate as second-line hormonal treatment. Swiss Group for Clinical Cancer Research (SAKK).
    Bernhard J; Castiglione-Gertsch M; Schmitz SF; Thürlimann B; Cavalli F; Morant R; Fey MF; Bonnefoi H; Goldhirsch A; Hürny C
    Eur J Cancer; 1999 Jun; 35(6):913-20. PubMed ID: 10533471
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Aromatase inhibitors and their potential clinical significance.
    Brodie AM; Wing LY; Goss P; Dowsett M; Coombes RC
    J Steroid Biochem; 1986 Nov; 25(5B):859-65. PubMed ID: 3807367
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Aromatase inhibition: 4-hydroxyandrostenedione (4-OHA, CGP 32349) in advanced prostatic cancer.
    Davies JH; Dowsett M; Jacobs S; Coombes RC; Hedley A; Shearer RJ
    Br J Cancer; 1992 Jul; 66(1):139-42. PubMed ID: 1637664
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Hypoglycaemia associated with formestane treatment.
    Brankin E; Gallagher A; Soukop M
    BMJ; 1997 Mar; 314(7084):869. PubMed ID: 9093099
    [No Abstract]   [Full Text] [Related]  

  • 69. Analysis by DNA polymerase alpha activity of human breast tumour proliferation and the effect of endocrine therapy.
    Coldham NG; Lai LC; Reed MJ; Ghilchik MW; Shaikh NA; James VH
    Br J Cancer; 1990 Aug; 62(2):263-6. PubMed ID: 2143678
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Hormone therapy of breast cancer in the metastatic phase in menopausal women].
    Namer M
    Presse Med; 1996 Nov; 25(35):1745-53. PubMed ID: 8977589
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Effect of 4-hydroxyandrost-4-ene-3,17-dione (formestane) on the bile secretion and metabolism of 4-(14)C-cholesterol to bile acids.
    Czerny B; Teister M; Juzyszyn Z; Modrzejewski A; Pawlik A
    Pharmacol Rep; 2005; 57(6):896-900. PubMed ID: 16382215
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Aromatase inhibition in advanced prostatic cancer: preliminary communication.
    Shearer RJ; Davies JH; Dowsett M; Malone PR; Hedley A; Cunningham D; Coombes RC
    Br J Cancer; 1990 Aug; 62(2):275-6. PubMed ID: 2201397
    [TBL] [Abstract][Full Text] [Related]  

  • 73. 4-hydroxyandrostenedione--further clinical and extended endocrine observations.
    Pickles T; Perry L; Murray P; Plowman P
    Br J Cancer; 1990 Aug; 62(2):309-13. PubMed ID: 2386749
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Perspectives of breast cancer from the ECCO-9 and from the 15th National Convention of Experimental and Clinical Oncology].
    Tumori; 1997; 83(6):979-82. PubMed ID: 9537919
    [No Abstract]   [Full Text] [Related]  

  • 75. Medical oncology: Endocrine-therapy-related symptoms and breast cancer.
    Buzdar AU
    Nat Rev Clin Oncol; 2009 Jun; 6(6):309-10. PubMed ID: 19483735
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Open comparative trial of formestane versus megestrol acetate in postmenopausal patients with advanced breast cancer previously treated with tamoxifen.
    Freue M; Kjaer M; Boni C; Joliver J; Jänicke F; Willemse PH; Coombes RC; Van Belle S; Pérez-Carrión R; Zieschang J; Ibarra de Palacios P; Rose C
    Breast; 2000 Feb; 9(1):9-16. PubMed ID: 14731578
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Metabolism of formestane in humans: Identification of urinary biomarkers for antidoping analysis.
    de la Torre X; Martinez Brito D; Colamonici C; Parr MK; Botrè F
    Steroids; 2019 Jun; 146():34-42. PubMed ID: 30904502
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Dermal repeated dose toxicity study of the anti-breast cancer drug Formestane cream in Bama minipig.
    Huang S; Wu Z; Chen Y; Li H; Zou L; Teichmann AT; Luo Y; Zhang L; Gao L
    Food Chem Toxicol; 2023 Aug; 178():113927. PubMed ID: 37406756
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Hormonal-therapy in patients with stage-iv breast-cancer at diagnosis.
    Zilembo N; Bajetta E; Noberasco C; Vicario G; Bichisao E; Daprile M
    Oncol Rep; 1995 Jul; 2(4):601-2. PubMed ID: 21597784
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Trilostane in the treatment of advanced breast cancer.
    Beardwell CG; Hindley AC; Wilkinson PM; Todd ID; Ribeiro GG; Bu'Lock D
    Cancer Chemother Pharmacol; 1983; 10(3):158-60. PubMed ID: 6861259
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.